Leading pharmaceutical corporation, AstraZeneca, is proposing a major acquisition, planning to buy Amolyt Pharma, a clinical-stage biotechnology company in France, in a deal that could rise to $1.05 billion. This acquisition is being guided by no less than three top-tier law firms.
According to the information available, U.K.-based firm Freshfields Bruckhaus Deringer is providing counsel to AstraZeneca on this deal. On Amolyt Pharma’s side, Jones Day and Cooley are offering their expertise to the French company and its shareholders.
This proposed acquisition underlines the increasing consolidation within the global pharmaceuticals and biotech sector, although further details on the specifics of the deal are currently undisclosed due to a paywall. This brief summary is based solely on the limited information that is publicly accessible.